Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TA(E)C-GP vs A(E)C-T in High Risk TNBC
NCT02641847Phase 3Active, not recruiting
- Sponsor
- Fudan University
- Start
- Jan 2016
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gemcitabine, cisplatin in triple-negative breast cancer (TNBC), sponsored by Fudan University. Started Jan 2016; status: active, not recruiting.
02
Drugs
gemcitabinecisplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02641847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02641847.